Enhanced oral bioavailability of the hydrophobic chemopreventive agent (Sr13668) in beagle dogs

Current Pharmaceutical Biotechnology

Volumn 14, Issue 4, 2013, Pages 464-469

  Banerjee, Aryamitra A ^a   Shen, Hao ^b   Hautman, Mathew ^c   Anwer, Jaseem ^c   Hong, Seungpyo ^a   Kapetanovic, Izet M ^d   Liu, Ying ^a,b   Lyubimov, Alexander V ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b 1120 Science and Engineering Offices   (United States)

^c Center for Biomedical Testing   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

Author keywords

Bioavailability; Chemoprevention; Nanoprecipitation; Oral drug delivery; Pharmacokinetics; Polymeric nanoparticles; Size distribution; Surface charges

Indexed keywords

ANTINEOPLASTIC AGENT; NANOPARTICLE; POLYGLACTIN; SR 13668; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; DOG; DRUG BIOAVAILABILITY; DRUG HALF LIFE; DRUG SOLUBILITY; FEMALE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; MALE; MAXIMUM PLASMA CONCENTRATION; NANOENCAPSULATION; NONHUMAN; PARTICLE SIZE; PLASMA CONCENTRATION-TIME CURVE; SINGLE DRUG DOSE; SPRAY DRYING; TANDEM MASS SPECTROMETRY; TIME TO MAXIMUM PLASMA CONCENTRATION; ULTRAVIOLET SPECTROPHOTOMETRY;

ADMINISTRATION, ORAL; ANIMALS; BIOLOGICAL AVAILABILITY; CARBAZOLES; CHEMISTRY, PHARMACEUTICAL; DOGS; FEMALE; LACTIC ACID; MALE; NANOPARTICLES; PARTICLE SIZE; POLYGLYCOLIC ACID; SOLUBILITY; SUSPENSIONS;

ANIMALIA; CANIS FAMILIARIS;

EID: 84878801866     PISSN: 13892010     EISSN: 18734316     Source Type: Journal    
DOI: 10.2174/1389201011314040012     Document Type: Article

References (17)

1. Chao, W.-R.; Yean, D.; Amin, K.; Green, C.; Jong, L., Computer-aided rational drug design: A novel agent (SR13668) designed to mimic the unique anticancer mechanisms of dietary indole-3-carbinol to block akt signaling. J. Med. Chem. 2007, 50(15), 3412-3415.
2. Jong, L.; Chao, W.-R.; Amin, K.; Laderoute, K.; Orduna, J.; Sato, B.; Rice, G., SR13668: A novel indole derived inhibitor of phospho-Akt potently suppresses tumor growth in various murine xenograft models. AACR Meeting Abstracts 2004, 2004, 849-d-850.
3. Jong, L.; Chao, W.-R.; Amin, K.; Yean, D., SR13668: An orally active inhibitor of phospho-Akt potently suppresses tumor growth and synergizes with chemotherapeutics both in vitro and in vivo. AACR Meeting Abstracts 2005, 2005, 401-a.
4. Kapetanovic, I. M.; Muzzio, M.; Hu, S.-C.; Crowell, J. A.; Rajewski, R. A.; Haslam, J. L.; Jong, L.; McCormick, D. L., Pharmacokinetics and enhanced bioavailability of candidate cancer preventative agent, SR13668 in dogs and monkeys. Cancer Chemother. Pharmacol. 2010, 65(6), 1109-1116.
5. Green, C. E.; Swezey, R.; Bakke, J.; Shinn, W.; Furimsky, A.; Bejugam, N.; Shankar, G. N.; Jong, L.; Kapetanovic, I. M., Improved oral bioavailability in rats of SR13668, a novel anti-cancer agent. Cancer Chemother. Pharmacol. 2011, 67(5), 995-1006.
6. Muller, R. H.; Peters, K., Nanosuspensions for the formulation of poorly soluble drugs - I. Preparation by a size-reduction technique. Int. J. Pharm. 1998, 160(2), 229-237.
7. Vauthier, C.; Bouchemal, K., Methods for the Preparation and Manufacture of Polymeric Nanoparticles. Pharmaceutical Research 2009, 26(5), 1025-1058.
8. Fessi, H.; Puisieux, F.; Devissaguet, J. P.; Ammoury, N.; Benita, S., Nanocapsule formation by interfacial polymer deposition following solvent displacement. International Journal of Pharmaceutics 1989, 55(1), R1-R4.
9. Schubert, S.; Delaney, J. T., Jr.; Schubert, U. S., Nanoprecipitation and nanoformulation of polymers: from history to powerful possibilities beyond poly(lactic acid). Soft Matter 2011, 7(5), 1581-1588.
10. Shen, H.; Banerjee, A. A.; Mlynarska, P.; Hautman, M.; Hong, S.; Kapetanovic, I. M.; Lyubimov, A. V.; Liu, Y., Enhanced oral bioavailability of a cancer preventive agent (SR13668) by employing polymeric nanoparticles with high drug loading. J. Pharm. Sci. 2012, 101(10), 3877-3885.
11. Shen, H.; Hong, S.; Prud'homme, R. K.; Liu, Y., Self-assembling process of flash nanoprecipitation in a multi-inlet vortex mixer to produce drug-loaded polymeric nanoparticles. J. Nanopart. Res. 2011, 13(9), 4109-4120.
12. Matsumura, Y.; Maeda, H., A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. Cancer Research 1986, 46(12), 6387-6392.
13. Allemann, E.; Leroux, J. C.; Gurny, R., Polymeric nano- and microparticles for the oral delivery of peptides and peptidomimetics. Adv. Drug Delivery Rev. 1998, 34(2-3), 171-189.
14. Leroux, J. C.; Cozens, R. M.; Roesel, J. L.; Galli, B.; Doelker, E.; Gurny, R., pH-sensitive nanoparticles: An effective means to improve the oral delivery of HIV-1 protease inhibitors in dogs. Pharm. Res. 1996, 13(3), 485-487.
15. Kesisoglou, F.; Panmai, S.; Wu, Y., Nanosizing - Oral formulation development and biopharmaceutical evaluation. Adv. Drug Delivery Rev. 2007, 59(7), 631-644.
16. Surendiran, A.; Sandhiya, S.; Pradhan, S. C.; Adithan, C., Novel applications of nanotechnology in medicine. Indian J. Med. Res. 2009, 130(6), 689-701.
17. Reid, J. M.; Walden, C. A.; Qin, R.; Ziegler, K. L. A.; Haslam, J. L.; Rajewski, R. A.; Warndahl, R.; Fitting, C. L.; Boring, D.; Szabo, E.; Crowell, J.; Perloff, M.; Jong, L.; Bauer, B. A.; Mandrekar, S. J.; Ames, M. M.; Limburg, P. J.; Canc Prevention, N., Phase 0 Clinical Chemoprevention Trial of the Akt Inhibitor SR13668. Cancer Prev. Res. 2011, 4(3), 347-353.